Drug search by name

Deferasirox Tablets For Oral Suspension and Hepatic impairment

Result of checking the interaction of drug Deferasirox Tablets For Oral Suspension and disease Hepatic impairment for safety when used together.

Check result:

Deferasirox Tablets For Oral Suspension <> Hepatic impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of deferasirox should be avoided in patients with severe hepatic impairment. The starting dose of deferasirox should be reduced by 50% in patients with moderate hepatic impairment. It is recommended to measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly or more frequently as clinically appropriate. Closely monitor patients with mild or moderate hepatic impairment for efficacy and adverse reactions that may require dose titration.

Deferasirox Tablets For Oral Suspension

Generic Name: deferasirox

Brand Name: Exjade, Jadenu, Jadenu Sprinkle

Synonyms: Deferasirox

What is Deferasirox Tablets For Oral Suspension?